Sexually Transmitted Diseases Vol. 32; No. 10: P. 625-629 (10..05) - Thursday, December 08, 2005
Hannelore M. Gotz, MD, MPH; Christian J.P.A. Hoebe, MD, PhD; Jan E.A.M. Van Bergen, MD, MPH; Irene K. Velhuijzen, MSc; Jan Broer, MD, PhD, MPH; F. De Groot, BA; M.J.C. Verhooren, BA; D.T. Van Schaik, MSc; A.J.J. Coenen, MSc; Jan H. Richardus, MD, PhD

Of 8,339 participants screened, 165 (2 percent) tested positive for Chlamydia trachomatis and were referred for treatment. The treating physician provided feedback on treatment and partner notification.

Including the effect of a reminder, the treatment rate of all index cases was 91 percent (150/165). For persons of non-Dutch ethnicity, the rate was 81 percent (25/31). Eighty-two percent of cases sought out a general practitioner for treatment, compared to 18 percent who consulted STD/MHS clinics. Eighty- five percent of cases were treated within two weeks. The confirmed partner treatment rate in the last six months was 49 percent (86/176); 57 percent (81/141) for current versus 14 percent (5/35) for other partners. An additional 18 percent (25/141) of current partners and 9 percent (3/35) of other partners were advised for patient referral.

"Home-based chlamydia screening and treatment through regular treatment facilities has proven to be effective in the Netherlands," the researchers concluded. "The necessity of a reminder to increase treatment rate and the lower treatment rate in non-Dutch high-risk groups deserve attention. Low confirmed treatment rate of current partners carries the potential of reinfection, and patient-delivered treatment should be expanded."
051208
AD052477

Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.